⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1864942 | 1.00 | — | — | |
| SCHEMBL1992557 | 1.00 | — | — | |
| SCHEMBL2090378 | 0.93 | — | — | |
| SCHEMBL7024273 | 0.93 | — | — | |
| SCHEMBL7761943 | 0.93 | — | — | |
| SCHEMBL2089864 | 0.84 | — | — | |
| SCHEMBL2497900 | 0.77 | — | — | |
| SCHEMBL18912345 | 0.77 | — | — | |
| SCHEMBL14026509 | 0.77 | — | — | |
| SCHEMBL23674758 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | claimed |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | claimed |
| CN-115835908-A | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2023-03-21 | — | — | CN | claimed |
| EP-4045151-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2022-08-24 | — | — | EP | claimed |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-06-23 | — | — | US | claimed |
| WO-2021076602-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-04-22 | — | — | WO | claimed |
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | claimed |
| CN-110582493-A | Benzoxazole derivatives as immunomodulators | 因赛特公司 | 2019-12-17 | — | — | CN | claimed |
| EP-3558985-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | claimed |
| WO-2018119266-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | claimed |
| EP-1421107-A1 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2004-05-26 | — | — | EP | claimed |
| US-20030153505-A1 | Dolastatin 15 derivatives | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-14 | — | — | US | claimed |
| US-20030050246-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-13 | — | — | US | claimed |
| US-20030045477-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-06 | — | — | US | claimed |
| WO-2003011896-A1 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-02-13 | — | — | WO | claimed |
| EP-1242455-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2002-09-25 | — | — | EP | claimed |
| EP-1232183-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2002-08-21 | — | — | EP | claimed |
| WO-2001038347-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| WO-2001038397-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| US-6143721-A | FOR TREATING CANCER IN MAMMALS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-07 | — | — | US | claimed |